The Defense Threat Reduction Agency (DTRA) in the US has awarded a new project agreement to Leidos to conduct clinical trials for Covid-19 therapeutics.

The cost-plus-fixed-fee agreement, which holds a $22m base value and 24 months of performance period, was awarded through the Medical CBRN Defense Consortium.

Through the new contract, Leidos plans to use a new clinical trial prototype, which uses an electronic data capture system to collect, evaluate and assess symptom severity.

This will enable real-time data collection to support rapid initiation, amendment and evaluation of clinical studies.

Leidos will use the new prototype to simultaneously conduct two clinical studies using new drug combinations for the treatment of Covid-19.

Designed to analyse the requirement of additional patients, Leidos trial prototype aims to provide quick evaluations and improvements as the study advances.

Leidos stated that these evaluations made by the new prototype could improve potential Phase III studies and also to demonstrate the efficacy using the selected drug combination.

Leidos Health Group president Liz Porter said: “This award reinforces our commitment to fighting this deadly pandemic.

“We are proud to conduct these clinical trials and support our customers’ mission to develop life-saving drugs, vaccines and therapeutics for the men and women of our armed forces.”

For this prototype project, the company will partner with Personal Health Insights, Syneos Health and Scope International USA .

Furthermore, Leidos noted that these clinal trials will help to pursue enhancements to military success by improving the long-term lung function and reducing neurocognitive deficits caused due to Covid-19.